Working… Menu

Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection (ESAMOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00455806
Recruitment Status : Unknown
Verified March 2007 by Technische Universität Dresden.
Recruitment status was:  Recruiting
First Posted : April 4, 2007
Last Update Posted : April 4, 2007
Information provided by:
Technische Universität Dresden

Brief Summary:
Successful H. pylori eradication therapy remains a challenge in medical practice. Despite promising data for first-line, second-line and rescue treatment options based on clinical trials as well as guidelines and expert recommendations, success rates can often not be reproduced in general practice. Rescue options for patients with failed initial or second-line therapy are definitely needed. The new fluoroquinolone moxifloxacin may represent an effective and save treatment option (in combination with a PPI and amoxicillin) for rescue therapy of H- pylori positive patients.However, optimal duration of therapy (7-day course vs 14-day course) has to be determined

Condition or disease Intervention/treatment Phase
Helicobacter Pylori Infection Chronic Gastritis Drug: esomeprazole Drug: moxifloxacin Drug: amoxicillin Phase 3

Detailed Description:
Successful H. pylori eradication therapy remains a challenge in medical practice. Currently, a PPI - based triple therapy containing clarithromycin, amoxicillin or nitroimidazole given for 7 days is the recommended first line treatment approach with an expected eradication success rate of approximately 80%. As second-line treatment option in case of failure, a RBC-based quadruple therapy is currently recommended curing another 80% of patients, leaving a subset of patients with persistent H. pylori infection. Resistance to fluoroquinolones is low in most countries,hence these compounds are potential candidates for second-line and rescue treatment. The new fluoroquinolone moxifloxacin launched by Bayer in 1999 for the treatment of respiratory tract infections, has a broad antibacterial spectrum comparable to levofloxacin but fewer phototoxic and central nervous system excitatory effects. The possible role of moxifloxacin in H. pylori eradication is since under clinical investigation

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection
Study Start Date : January 2007
Estimated Study Completion Date : February 2008

Primary Outcome Measures :
  1. Efficacy of a combination of esomeprazole (E), moxifloxacin (M) and amoxicillin (A) for third line therapy of H. pylori infection.
  2. Comparison of EMA 7 days versus EMA 14 days. Hypothesis: superiority of EMA 14 days 4 weeks after end of eradication therapy

Secondary Outcome Measures :
  1. Tolerability,safety, post treatment resistance, influence of host genetics (CYP status) and pathogenicity factors of H. pylori on treatment success.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male/female, age >/=18 years
  • Helicobacter pylori infection proven by histology and culture
  • indication for eradication therapy according to the Maastricht-III
  • at least one failed prior eradication attempt
  • pretherapeutic resistance testing (culture)
  • written informed consent

Exclusion Criteria:

  • in vitro resistance to moxifloxacin or amoxicillin
  • current complicated peptic ulcer disease
  • daily intake of NSAIDs
  • co-medication with drugs known to interact with the study medication
  • history of gastric surgery/vagotomy
  • medical treatment for depression, known suicide attempt
  • severe cardiological diseases such as bradyarrythmia, QT changes
  • malignant disease
  • gravidity, nursing
  • women with child bearing potential must perform contraceptive measures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00455806

Layout table for location contacts
Contact: Stephan Miehlke, MD, PhD +493514585645
Contact: Andrea Morgner, MD, PhD +493514584460

Layout table for location information
Gastroenterologist, private praxis Recruiting
Cologne, Germany, 51063
Contact: Elke Bästlein, MD         
Principal Investigator: Elke Bästlein, MD         
Med. Dept. I, Gastroenterology, University Hospital, Technical University of Dresden Recruiting
Dresden, Germany
Contact: Andrea Morgner-Miehlke, MD, PhD         
Principal Investigator: Andrea Morgner-Miehlke, MD, PhD         
Gastroenterologist / private praxis Recruiting
Görlitz, Germany
Contact: Christian Haferland, ME         
Principal Investigator: Christian Haferland, MD         
Medical Department, University Homburg/Saar Recruiting
Homburg/Saar, Germany
Contact: Gerhard Treiber, MD, PhD         
Principal Investigator: Gerhard Treiber, MD, PhD         
Medical Dept. I, University Hpspital Kiel Recruiting
Kiel, Germany
Contact: Stefan Hellmig, MD, PhD         
Principal Investigator: Stefan Hellmig, MD, PhD         
Gastroenterologist / private praxis Recruiting
Munich, Germany
Contact: Wilfried Höchter, MD         
Contact: Josef Weingart         
Principal Investigator: Wilfried Höchter, MD         
Technical University of Munich, Medical Dept. II Recruiting
Munich, Germany
Contact: Alexander Meining, MD, PhD         
Principal Investigator: Alexander Meining, MD, PhD         
Gastroenterologist / private praxis Recruiting
Oldenburg, Germany
Contact: Michael Neumeyer, MD         
Principal Investigator: Michael Neumeyer, MD         
Med. Department, Jung-Stilling Krankenhaus Recruiting
Siegen, Germany
Contact: Andreas Leodolter, MD         
Contact: Joachim Labenz, MD, PhD         
Principal Investigator: Andreas Leodolter, MD         
Sponsors and Collaborators
Technische Universität Dresden
Layout table for investigator information
Principal Investigator: Stephan Miehlke, MD, PhD Medical Department I, Gastroenterology, Universityhospital, Technical University Dresden
Study Chair: Norbert Lehn, MD, PhD Institue for Medical Microbiology, University of Regensburg
Study Chair: Enno Jacobs, MD, PhD Institute for Medical Microbiology, Technical University of Dresden
Study Chair: Manfred Stolte, MD, PhD Institute for Pathology, Klinikum Bayreuth


Layout table for additonal information Identifier: NCT00455806     History of Changes
Other Study ID Numbers: ESAMOX_01_2007
EudraCT Numberr 2006-004323-10
First Posted: April 4, 2007    Key Record Dates
Last Update Posted: April 4, 2007
Last Verified: March 2007
Keywords provided by Technische Universität Dresden:
Helicobacter pylori
rescue therapy
eradication therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors